23 results
Thumbnail

D1.189 - Does Allergen Immunotherapy Add Clinically Meaningful Benefit in Paediatric Asthma and Allergic Rhinitis? A 36-Month Real-World Comparison

Thumbnail

D1.192 - Combined Polymerized Pollen and Animal Dander Immunotherapy Improves Rhinoconjunctivitis and Asthma in Polysensitized Patients: Real-World Evidence

Thumbnail

D1.194 - Real-World Effectiveness of Polymerized Dog Allergen Immunotherapy in Allergic Rhinoconjunctivitis and Asthma

Thumbnail

D1.186 - Three years treatment with HDM injection allergen immunotherapy, omalizumab, or combination therapy in allergic asthma

Thumbnail

D1.198 - Efficacy of Cat Allergen Immunotherapy: A Multicenter Prospective Study

Thumbnail

D1.257 - Hereditary Angioedema in Bulgaria (1972-2025): A Longitudinal Comparative Study of Trends in Diagnosis, Mortality, and the Impact of Modern Therapies

Thumbnail

D1.259 - Icatibant Use During Pregnancy: A South African Case Series

Thumbnail

D1.261 - Phenotypic and Immunological Profiles of Chronic Urticaria: A Cross- Sectional Study From South India

Thumbnail

D1.250 - Real-World Effectiveness and Safety of Icatibant for Hereditary Angioedema in China: An Interim Analysis of the EASTERN Study

Thumbnail

D1.253 - Probiotic Co-administration to Improve Gastrointestinal Tolerability of Berotralstat in Hereditary Angioedema: a multicenter case series from the ITACA network

Thumbnail

D1.254 - Comparison Between Classical and Updated Classifications in Patients Diagnosed with Isolated Angioedema: Finally, Did We Find the Ideal One?

Thumbnail

D1.255 - Is it Angioedema? Unmasking a complete Melkersson-Rosenthal Syndrome

Thumbnail

D1.256 - Chronic Inducible Urticaria in Real Life: A Single-Centre Retrospective Cohort

Thumbnail

D1.258 - First real-life experiences with Sebetralstat as oral on-demand treatment for acute HAE attacks documented in a global angioedema disease registry

Thumbnail

D1.260 - Clinical Characteristics and Hospitalization Patterns in Chronic Spontaneous Urticaria Patients in Bulgaria

Thumbnail

D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset

Thumbnail

D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study

Thumbnail

D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes

Thumbnail

D3.424 - Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria

Thumbnail

D3.426 - Predicting response to omalizumab in patients with chronic spontaneous urticaria: The first results of the global multicenter UCARE SCOPUS project